Source: European Medicines Agency (EU) Revision Year: 2018 Publisher: Immunomedics GmbH, Otto-Röhm-Straße 69, D-64293 Darmstadt, Germany
LeukoScan 0.31 mg, powder for solution for injection.
Pharmaceutical Form |
---|
Powder for solution for injection. |
Kit for the preparation of 99mTc-labelled LeukoScan.
Each 3 ml vial contains 0.31 mg sulesomab (IMMU-MN3 murine Fab′-SH antigranulocyte monoclonal antibody fragments) for the preparation of 99mTc labelled LeukoScan. The kit does not include the radioisotope.
Excipients: Sucrose (37.8 mg).
For a full list of excipients, see section 6.1.
Active Ingredient | Description | |
---|---|---|
Technetium ⁹⁹ᵐTc sulesomab |
Technetium ⁹⁹ᵐTc sulesomab (IMMU-MN3 murine Fab′-SH antigranulocyte monoclonal antibody fragments) recognizes an antigenic structure shared by a surface glycoprotein (NCA-90) of granulocytes and the tumour marker. It is indicated for diagnostic imaging for determining the location and extent of infection/inflammation in bone in patients with suspected osteomyelitis, including patients with diabetic foot ulcers. |
List of Excipients |
---|
Stannous chloride dihydrate |
One vial prepared so as to contain 0.31 mg lyophilised LeukoScan monoclonal antibody fragment.
The Type I glass vial is closed with a grey butyl rubber stopper with a green flip-off seal.
Pack size: one vial per carton container.
Immunomedics GmbH, Otto-Röhm-Straße 69, D-64293 Darmstadt, Germany
EU/1/97/032/001
Date of first authorisation: 14 February 1997
Date of lastest renewal: 20.05.2007
Drug | Countries | |
---|---|---|
LEUKOSCAN | Spain, Lithuania |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.